A court battle between a giant in the drug-making industry and a small Cambridge-based laboratory in a dispute over alleged patent-rights violations begins this week in U.S. District Court.
California-based Amgen Inc., maker of Epogen, a product used to treat kidney dialysis patients, claims Transkaryotic Therapies Inc. of Cambridge and its collaborator Aventis infringed on Amgen’s patents for the anemia drug.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
